Signal Genetics, the US-based molecular diagnostic company, has announced that its proprietary gene expression profiling (GEP) based test, Myeloma Prognostic Risk Signature┬« (MyPRS), has received conditional ‘Investigational Drug Exemption’ approval to assist with entry criteria for an upcoming clinical trial. The trial (2012-02 Total Therapy 5B), conducted at the University of Arkansas for Medical Sciences (UAMS), USA, is investigating the safety and efficacy of an investigational treatment strategy for high-risk myeloma patients and will use MyPRS to identify newly diagnosed myeloma patients with GEP-defined high-risk myeloma. Results from the trial are expected to further validate MyPRS as a potential prognostic tool for myeloma patients.


Read full article